Former FDA Officials: There’s Opportunity to Rebuild the Agency — But Not the Way It Was

Why It Matters

A restructured, politically insulated FDA could accelerate drug approvals while preserving scientific integrity, directly affecting pharma innovation and public health outcomes.

Key Takeaways

• FDA’s 40‑year center structure deemed outdated by former officials
• Pazdur proposes disease‑specific centers, e.g., oncology, neurology, infectious disease
• Political appointees allegedly breaching scientific firewall, prompting staff exits
• Acting commissioner and interim directors limit agency stability until permanent hires
• Recruiting academic talent could alleviate workload and restore independence

Pulse Analysis

The Food and Drug Administration’s organizational model—split between CDER for small‑molecule drugs and CBER for biologics—was designed in an era when therapeutic categories were far fewer. Decades of scientific convergence have rendered that split increasingly artificial, leading veterans like Rick Pazdur to call it an anachronism. By preserving siloed review pathways, the agency risks duplicated effort, slower decision‑making, and a talent drain as experts seek more modern, integrated environments.

Pazdur’s blueprint envisions disease‑specific centers—oncology, neurology, cardiovascular, infectious disease, and even manufacturing—each staffed with multidisciplinary teams that mirror the complexity of today’s therapies. Such a model could streamline review timelines, align regulatory expertise with therapeutic nuances, and create clearer accountability. However, the proposal collides with a politically charged climate; recent appointees have been accused of blurring the firewall that separates science from policy, prompting senior scientists like Nicole Gormley to depart. Restoring that firewall is essential not only for credibility but also for attracting top talent from academia and industry.

Implementation will depend on stable leadership. The current acting commissioner and interim CDER/CBER directors signal uncertainty, and permanent appointments are unlikely before the November midterms. A coordinated effort—combining permanent, bipartisan leadership with a strategic infusion of academic experts—could revitalize the FDA’s mission. For pharmaceutical companies, a more agile, science‑first regulator promises faster market entry and clearer pathways, while patients stand to benefit from quicker access to innovative treatments.